Revolution Medicines

109 articles about Revolution Medicines

• 

  Revolution Medicines Scores With Up to $500 Million in Oncology Collaboration With Sanofi

  7/18/2018

  In April Bay Area biotech Revolution Medicines completed its pivot from a company focused on antifungal treatments to an oncology business. This morning Revolution’s shift paid off with a development deal worth up to $500 million with Sanofi.
• 

  Revolution Medicines Raises Another $56 Million and Completes Pivot from Antifungal to Cancer Com...

  4/24/2018

  Revolution Medicines closed on a Series B financing round worth $56 million. The round was led by Nextech Invest, with participation from Casdin Capital, Schroder Adveq, The Column Group, Third Rock Ventures and undisclosed institutional investors.

• REVOLUTION Medicines Raises $56 Million Series B Financing

  4/24/2018

  REVOLUTION Medicines, Inc. announced it has raised $56 million in a Series B financing to support its ongoing R&D programs and general business activities.

• Revolution Medicines Appoints Vincent Miller, M.D. To Board Of Directors

  10/6/2017

• Revolution Medicines Appoints Cancer Leader Dr. Stephen Kelsey As President Of Research And Development

  3/20/2017

• Launched in 2015 with $45 Million, Bay Area Revolution Medicines Scores $25 Million

  12/21/2016

• Revolution Medicines Names Academic Co-Founder, Michael Fischbach, Ph.D., And Senior Advisor, Eric Gordon, Ph.D.

  6/14/2016

• Rationally Designed Antifungal Compounds That Evade Resistance Reported In Nature Chemical Biology By Scientific Founder Of Revolution Medicines

  6/1/2015

• Revolution Medicines Appoints Pharmaceutical Commercial Executive Elizabeth McKee Anderson To Board Of Directors

  4/9/2015